Incidence, mortality, and survival trends of soft tissue and bone sarcoma in Switzerland between 1996 and 2015

Kollár, Attila; Rothermundt, Christian; Bode, Beata; Baumhoer, Daniel; Arndt, Volker; Feller, Anita

doi:10.1016/j.canep.2019.101596

Cited by 48 publications

(53 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For male, ASR-W was equivalent (0.34 versus 0.32). A recent population-based study from Swiss cancer registries showed similar results [15]. In contrast, others studies based on older inclusion period of sarcoma diagnosis found an ASR-W slightly higher for osteosarcoma [8,16].…”

Section: Discussionsupporting

confidence: 53%

Incidence and time trends of sarcoma (2000–2013): results from the French network of cancer registries (FRANCIM)

et al. 2020

View full text Add to dashboard Cite

Background: The exhaustive collection of new sarcoma cases and their second histologic review offer a unique opportunity to study their incidence and time trends in France according to the major subtypes. Methods: Data were collected from population-based cancer registries covering 22% of the French population. Crude and world age-standardized incidence rates (ASR) were estimated according to anatomic, histological and genetic groups, age and sex over the 2010-2013 period. Results: Time trends in incidence were calculated by the annual percent change over the 2000-2013 period. During the most recent period (2010-2013), 3942 patients with sarcoma were included. The ASR of soft-tissue and bone sarcomas, and gastro-intestinal stromal tumors (GIST) were 2.1, 1.0 and 0.6, respectively. For the four most frequent histological subtypes (unclassified, leiomyosarcoma, GIST and liposarcoma), the ASR ranged from 0.4 to 0.7. ASRs were 1.9 for complex genomic and 1.3 for recurrent translocation sarcomas. The timetrend analysis showed a significant increase of sarcoma incidence rate between 2000 and 2005, which stabilized thereafter. Incidence rates increased for four histological subtypes (GIST, chondrosarcoma, myxofibrosarcoma, solitary fibrous tumors) and decreased for three (leiomyosarcomas, Kaposi sarcoma and fibrosarcoma). Conclusion: To our knowledge, this study is the first to investigate sarcoma incidence based on a systematic pathological review of these cancers and on the updated sarcoma classifications. Due to the paucity of literature on sarcomas, future studies using data from population-based cancer registries should consider a standardized inclusion criterion presented in our study to better describe and compare data between countries.

show abstract

Section: Discussionsupporting

confidence: 53%

Incidence and time trends of sarcoma (2000–2013): results from the French network of cancer registries (FRANCIM)

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Therefore, our findings of increased incidence rates suggest an interaction between genetic predisposition and non-genetic factors, such as changes in lifestyle and environmental exposures. It has also been postulated that increasing rates of soft tissue sarcomas could be the result of better diagnostic criteria [37]. However, we would not expect better diagnostic tools, such as molecular testing, to impact well-differentiated or myxoid liposarcoma because these sub-types are easily identified by histology alone.…”

Section: Discussionmentioning

confidence: 97%

Increasing Incidence of Liposarcoma: A Population-Based Study of National Surveillance Databases, 2001–2016

Bock

Hoffmann

Jiang

et al. 2020

IJERPH

View full text Add to dashboard Cite

Rare cancers, affecting 1 in 5 cancer patients, disproportionally contribute to cancer mortality. This research focuses on liposarcoma, an understudied rare cancer with unknown risk factors and limited treatment options. Liposarcoma incident cases were identified from the U.S. Surveillance, Epidemiology, and End Result (SEER) program and the combined SEER-National Program of Cancer Registries (CNPCR) between 2001-2016. Incidence rates (age-adjusted and age-specific), 5-year survival, and the time trends were determined using SEER*stat software. Three-dimensional visualization of age-time curves was conducted for males and females. SEER liposarcoma cases represented~30% (n = 11,162) of the nationwide pool (N = 37,499). Both sources of data showed males accounting for~60% of the cases; 82%-86% cases were identified among whites. Age-adjusted incidence was greater among males vs. females and whites vs. blacks, whereas survival did not differ by sex and race. The dedifferentiated (57.2%), pleomorphic (64.1%), and retroperitoneal (63.9%) tumors had the worse survival. Nationwide, liposarcoma rates increased by 19%, with the annual percent increase (APC) of 1.43% (95% confidence interval (CI): 1.12-1.74). The APC was greater for males vs. females (1.67% vs. 0.89%) and retroperitoneal vs. extremity tumors (1.94% vs. 0.58%). Thus, incidence increased faster in the high-risk subgroup (males), and for retroperitoneal tumors, the low-survival subtype. The SEER generally over-estimated the rates and time trends compared to nationwide data but under-estimated time trends for retroperitoneal tumors. The time trends suggest an interaction between genetic and non-genetic modifiable risk factors may play a role in the etiology of this malignancy. Differences between SEER and CNCPR findings emphasize the need for nationwide cancer surveillance.have a considerable impact on the overall cancer outcomes. Limited treatment options, high costs of existing treatments, and frequent misdiagnosis of rare cancers burden patients, physicians, and health systems [4]. The lack of epidemiological knowledge about the risk factors associated with many rare cancers precludes the development of viable prevention, making it one of the most dramatic unresolved public health problems [1,3,5]. In comparison, well-studied cancers such as colorectal cancer, which constitutes a smaller portion of the overall cancer cases (13%), has had significant progress in cancer control and prevention [5,6]. The existing gaps in research and treatment are reflected in rare cancer survival rates. The 5-year survival for rare cancers is worse compared to common cancers: 49% vs. 63% in Europe [5]; and the U.S., 55% vs. 75% among males and 60% vs. 74% among females [4]. In light of these facts, population-based surveillance of rare cancers and their descriptive epidemiology provide the foundation for advancing etiological and clinical research with the ultimate goal of reducing the public health burden of rare cancers.This research focuses on the under-studied rare cancer...

show abstract

“…According to the latest cancer statistics in United States 2019, the estimated new cancer cases and deaths for bones, joints and soft tissue were 16,250 and 6,930 cases, respectively [1]. Data from other countries showed the Ivyspring International Publisher age-standardized incidence in soft tissue sarcoma was 2.8-4.5/100,000 person-years while it was 0.2-2.1/ 100,000 for bone sarcoma [2][3][4]. As to the mortality, the age-standardized rate in Switzerland from 2011 to 2015 was 1.42 per 100,000 person-years in soft tissue sarcoma and 0.42 in bone sarcoma [3].…”

Section: Introductionmentioning

confidence: 99%

The Nomogram for Early Death in Patients with Bone and Soft Tissue Tumors

Xu¹,

Xu²,

Wu³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Objectives: The present study aimed to evaluate the early mortality rate and associated factors for early death in bone and soft tissue tumors, and to construct predictive nomogram. Methods: Patients diagnosed between 2010 and 2015 in the Surveillance, Epidemiology, and End Results (SEER) dataset were enrolled. The early death (survival time ≤ 3 months) rate was calculated and associated risk factors were evaluated by the logistic regression models. The significant factors were used to construct predictive nomograms. Results: A total of 2,003 (8.5%) patients died within 3 months after cancer diagnosis, among whom 1,146 (4.9%) patients died from cancer-specific cause. Older age (19-50 and >50 years), grade (III and IV), reginal or distant stage were associated with higher odds of total, cancer-specific and non-cancer-specific early death. T2 stage, metastasis to brain and lung were risk factors for total and cancer-specific early death. Surgical interventions significantly decreased the odds of total, cancer-specific and non-cancer-specific early death. Female and black race were associated with lower odds of non-cancer-specific early death. The area under the curve (AUC) of the nomograms for total early death, cancer-specific and non-cancer-specific early death prediction was 88.0%, 89.0% and 83.2%, respectively. Conclusions: A total of 8.5% patients with bone and soft tissue tumors suffered early death. Several risk factors were associated with higher odds of early death while surgery can decrease the possibility of early death. Nomograms based on all related factors can be used to estimate the early death in bone and soft tissue tumors.

show abstract

Incidence, mortality, and survival trends of soft tissue and bone sarcoma in Switzerland between 1996 and 2015

Cited by 48 publications

References 32 publications

Incidence and time trends of sarcoma (2000–2013): results from the French network of cancer registries (FRANCIM)

Incidence and time trends of sarcoma (2000–2013): results from the French network of cancer registries (FRANCIM)

Increasing Incidence of Liposarcoma: A Population-Based Study of National Surveillance Databases, 2001–2016

The Nomogram for Early Death in Patients with Bone and Soft Tissue Tumors

Contact Info

Product

Resources

About